
Evotec and Celmatix enter strategic partnership
Under the terms of the strategic R&D collaboration, Celmatix Inc. (New York) will utilise its proprietary multi-omics Reproductive Atlas platform...

Novo secures Dicerna’s RNAi liver assets
Under the deal, which includes potential treatments for NASH, orphan liver diseases, obesity and diabetes, Dicerna could theoretically earn...

Research team improves safety of LGMD2A gene therapy
Limb-girdle muscular dystrophy type 2A (LGMD2A or LGMDR1) is a neuromuscular disorder hat causes progressive muscle weakness and has no cure. The...

Successful EFIB in Brussels
More than 260 companies with 480 delegates from 30 countries joined for this year’s “European Forum for industrial Biotechnology and Bioeconomy”...

Immatics and Celgene enter $1.5bn deal
Under the agreement, Celgene secures exclusive options to three "T-Cell receptor engineered T-cell therapy" (TCR-T) solid tumour targets...

MS: Polpharma joins forces with Sandoz
Natalizumab, which is currently being marketed by Biogen, is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is a...

Azeria Therapeutics bags €37.3m in Series B financing round
Series A lead investor CRT Pioneer Fund co-financed the Series B financing round. Azeria said it will use the proceeds to develop its preclinical...